Will Being On China’s New Essential Drugs List Be A Boon Or A Bane?
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharma execs debate the issue while awaiting release of the pared-down list, now anticipated sometime in June.
You may also be interested in...
China Paring Down Essential Medicines List In Sweeping Health System Reforms
[Editor's note: This is part three in a new series on China's wide-ranging plans to reform the country's health system, including its hospitals, insurance schemes, and access to medicines. Part one in the series appeared in PharmAsia News Oct. 30, 2008, and part two appeared Nov. 13, 2008.]
Bayer Schering Partners With Polish Biotech Firm To Provide Recombinant Insulin To China's Exploding Diabetics Population
Bayer's antidiabetes drug Glucobay (acarbose), an alpha-glucosidase inhibitor, is already one of the company's strongest products in China.
New Vaccine Partnership With GSK Could Act As Lifeline For Chinese Biotech Firm Neptunus In Troubled Financial Seas
GlaxoSmithKline provides leading-edge vaccine technology and equipment, along with an injection of cash totaling almost $30 million, while Neptunus contributes its production facilities and access to the Chinese market.